King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Taher Al-Tweigeri
Dr. Taher Al-Tweigeri (also known as Taher Tweigieri) is a senior Consultant Medical Oncologist specialising in breast cancer, and one of the most established breast cancer specialists in Riyadh, Saudi Arabia. His research and clinical work has shaped Saudi breast cancer guidelines for over two decades.
- Consultant — Medical Oncology Section, Oncology Centre, at a leading tertiary cancer centre in Riyadh
- Lead author on the Saudi breast cancer consensus on management of early and metastatic disease (Oncol Ther, 2025)
- Principal investigator on landmark phase 1/2 trial adding tocilizumab to cisplatin/docetaxel in triple-negative breast cancer (Sci Rep 2026)
- Long-standing role in Saudi Arabia's largest single-centre breast cancer registry (1,035+ patients, 12-year follow-up)
- Received speaking honoraria and advisory roles with Roche, Novartis, and Lilly (disclosed in peer-reviewed publication)
Qualifications & Credentials
Medical Degrees
- MBBS / MD — Information not publicly available.
- Internal Medicine Residency — Information not publicly available.
- Medical Oncology Specialty Training — Information not publicly available.
Fellowships & Special Training
- Information not publicly available.
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) registration
- Information not publicly available.
Areas of Expertise
Major Conditions Treated
- Breast Cancer (luminal A/B, HER2-enriched, triple-negative)
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- BRCA-Associated Breast Cancer
- HER2-Positive Breast Cancer
- Ductal Carcinoma In Situ (DCIS)
- Obesity-Related Breast Cancer
Sub-specialties
- Triple-Negative Breast Cancer (TNBC) Innovation: Principal investigator on novel IL-6 pathway targeting with tocilizumab plus cisplatin/docetaxel — a landmark contribution to best TNBC treatment in Saudi Arabia.
- Neoadjuvant Chemotherapy: Pioneer of doxorubicin-docetaxel-cisplatin regimens in locally advanced breast cancer.
- Arab Women Breast Cancer Epidemiology: Lead contributor to molecular subtype research and obesity-breast cancer associations in Saudi and Arab women.
Advanced Procedures & Treatments
- Neoadjuvant Chemotherapy (doxorubicin, taxanes, cisplatin-based)
- Adjuvant Chemotherapy for Early Breast Cancer
- HER2-Targeted Therapy (Trastuzumab, Pertuzumab, T-DXd)
- CDK 4/6 Inhibitor Therapy
- Endocrine Therapy (Aromatase Inhibitors, Tamoxifen, Fulvestrant)
- Antibody-Drug Conjugate Therapy
- Investigational Trials (Tocilizumab, Novel Targeted Therapies)
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (Cancer Centre of Excellence), Riyadh, Saudi Arabia — Consultant, Breast Cancer Section, Medical Oncology Department (Current)
Past Affiliations
- Information not publicly available.
Academic & Research Roles
- Faculty / Investigator — Breast Cancer Research Programme, KFSHRC Molecular Oncology Department
- Adjunct Faculty — Alfaisal University, Riyadh — Information not publicly available.
Key Achievements
- Co-author on the 2025 Saudi national breast cancer consensus guideline
- Principal investigator on the tocilizumab + cisplatin/docetaxel phase 1/2 TNBC trial
- Senior contributor to Saudi breast cancer molecular subtyping research (Luminal A, B, HER2, TNBC)
- Long-term prognostic research on young-age, obesity, and BRCA carriers in Saudi breast cancer
- Senior author / collaborator on over 100 peer-reviewed publications on breast cancer biology and treatment
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Clinical Oncology (ASCO) — Information not publicly available.
- European Society for Medical Oncology (ESMO) — Information not publicly available.
- Saudi Oncology Society
Research & Publications
Published Papers (Selected)
- Al-Tweigeri T, Akhtar S, Alzahrani M, Elhassan T, Suleman K, AlSayed A et al. Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial. Sci Rep. 2026. DOI: 10.1038/s41598-026-38465-z
- Al-Tweigeri TA et al. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol. 2010;27(3):571-577.
- Alessy S, AL-Tweigeri T, Al-Zahrani AS et al. Molecular Subtypes of Breast Cancer in Arab Women: Distribution and Prognostic Insights. 2025 (PMC11893967).
- Elkum N, Al-Tweigeri T, Ajarim D, Al-Zahrani A, Bin Amer SM, Aboussekhra A. Obesity is a significant risk factor for breast cancer in Arab women. 2015 (PMC4532295).
- Alaklabi S, Akhtar S, AL-Tweigeri T et al. Management of Early and Metastatic Breast Cancer: Saudi Consensus. Oncol Ther. 2025. DOI: 10.1007/s40487-025-00404-9
Ongoing Research & Clinical Interests
- Triple-negative breast cancer novel therapies
- Molecular subtypes in Arab women
- Obesity and breast cancer risk
- microRNA and circulating biomarkers in breast cancer
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Medical Oncology Consultation | SAR 600 – SAR 1,800 | $160 – $480 |
| Neoadjuvant Chemotherapy (full course) | SAR 80,000 – SAR 250,000 | $21,300 – $66,700 |
| HER2-Targeted Therapy (annual) | SAR 200,000 – SAR 400,000 | $53,000 – $106,000 |
| CDK 4/6 Inhibitor Therapy (monthly) | SAR 20,000 – SAR 40,000 | $5,300 – $10,700 |
| Clinical Trial Enrollment (novel therapies) | Varies — subsidised by trial | Varies — subsidised by trial |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Taher Al-Tweigeri use as a Medical Oncologist?
Dr. Taher Al-Tweigeri uses advanced breast cancer treatments including novel IL-6 pathway targeting (tocilizumab in TNBC), HER2-targeted therapy and antibody-drug conjugates, CDK 4/6 inhibitors, molecular profiling-guided treatment, and active clinical trial enrolment for investigational agents. International virtual consultations are available through Cancer Rounds.
2. What conditions does Dr. Taher Al-Tweigeri specialize in treating?
Dr. Taher Al-Tweigeri specialises in all breast cancer subtypes — early-stage, locally advanced, and metastatic disease, including triple-negative, HER2-positive, hormone receptor-positive, and BRCA-related breast cancer. He is a senior breast cancer oncologist in Riyadh and a top choice for patients seeking evidence-based, trial-backed breast cancer care.
3. How do I book an appointment with Dr. Taher Al-Tweigeri?
Appointments with Dr. Taher Al-Tweigeri can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Taher Al-Tweigeri?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Taher Al-Tweigeri, including Saudi Arabia medical visa invitation letters, airport transfers, and local accommodation coordination in Riyadh.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation (Arabic, English, and more), financial counselling, and pre-travel virtual consultations to review medical records before arrival in Riyadh.
6. Does Dr. Taher Al-Tweigeri offer second opinions as a Medical Oncologist?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with Dr. Taher Al-Tweigeri, an expert Medical Oncologist in Riyadh, Saudi Arabia.
